Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2015

View Archived Issues

Recent FDA orphan drug designations

AstraZeneca profiles pipeline highlights of third quarter 2015

MedImmune initiates first-in-human study of MEDI-4166 for type 2 diabetes

Discovery of small-molecule bacterial riboswitch inhibitors

FUJIFILM to begin phase I trial of FF-10101 in the U.S.

Boehringer Ingelheim establishes new collaborations to advance research in IBD

Shionogi and GSK to independently develop collaboration on cephalosporin antibiotics

FDA issues complete response letter for Cotempla XR-ODT NDA

Astellas Pharma discloses preclinical and first-in-human phase I results of ASP-5878

4D Pharma obtains approval to conduct phase I trial of Thetanix

Afferent Pharmaceuticals begins phase II trial of AF-219 for cough in IPF

XF-73 receives FDA QIDP designation

Partial hold removed from encenicline trial for cognitive impairment in schizophrenia

LEO Pharma to acquire global dermatology portfolio from Astellas Pharma

Novel inhibitors block LIM kinase activity in cancer cell lines

New phase II trial investigates combination of CMB-305 and atezolizumab for soft tissue sarcoma

Boehringer Ingelheim announces multibillion-euro R&D investment program

MD Anderson explores new lirilumab combination regimen for MDS

Mitsubishi Tanabe Pharma patents CYP11B2 inhibitors

Incyte describes Brd4 inhibitors

Taisho Pharmaceutical divulges EGLN1 inhibitors

Stanford University reports development of anti-CD99 MAbs

GamaMabs Pharma presents anti-HER4 human MAbs

World Pneumonia Day: reducing delivery restraints and fighting antibiotic resistance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...